Atezolizumab
- Generic Name
- Atezolizumab
- Brand Names
- Tecentriq
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1380723-44-3
- Unique Ingredient Identifier
- 52CMI0WC3Y
- Background
Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was granted FDA approval on 18 October 2016. In November 2022, the manufacturer (Genentech) voluntarily withdrew the use of atezolizumab for the treatment of urothelial carcinoma, previously approved under the FDA's Accelerated Approval Program. The rest of atezolizumab indications remain unaffected.
- Indication
Atezolizumab has approved indications for the following conditions:
Non-Small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer (SCLC)
Hepatocellular Carcinoma (HCC)
Melanoma
Alveolar Soft Part Sarcoma (ASPS)
- Associated Conditions
- Metastatic Alveolar Soft Part Sarcoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Triple-Negative Breast Cancer, Unresectable Alveolar Soft Part Sarcoma, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Melanoma
- Associated Therapies
- -
A Study Evaluating the Efficacy and Safety of Adjuvant Platinum-Doublet Chemotherapy, With or Without Atezolizumab, in Patients Who Are ctDNA Positive After Complete Surgical Resection of Stage IB to Select IIIB Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-11-02
- Last Posted Date
- 2021-06-16
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT04611776
Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2020-10-30
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Jeffrey Clarke
- Target Recruit Count
- 3
- Registration Number
- NCT04610684
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸University of Illinois Cancer Center, Chicago, Illinois, United States
🇺🇸St. Vincent Anderson Regional Hospital, Anderson, Indiana, United States
The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy
- Conditions
- Interventions
- Drug: Oncology DrugsDrug: ErlotinibDrug: TrastuzumabDrug: Trastuzumab emtansineDrug: PertuzumabDrug: LapatinibDrug: EverolimusDrug: VemurafenibDrug: CobimetinibDrug: AlectinibDrug: BrigatinibDrug: PalbociclibDrug: PonatinibDrug: VismogedibDrug: ItacitinibDrug: IpatasertibDrug: EntrectinibDrug: AtezolizumabDrug: NivolumabDrug: IpilimumabDrug: PemigatinibDrug: PralsetinibDrug: SelpercatinibDrug: TalazoparibDrug: TepotinibDrug: Alpelisib
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Fondazione per la Medicina Personalizzata
- Target Recruit Count
- 400
- Registration Number
- NCT04591431
- Locations
- 🇮🇹
I.R.S.T. Srl Irccs, Meldola, Italy
🇮🇹Ospedale Classificato Sacro Cuore - Don Calabria, Negrar, Italy
🇮🇹I.R.C.C.S. Istituto Oncologico Veneto, Padova, Italy
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 920
- Registration Number
- NCT04589845
- Locations
- 🇺🇸
Southern Cancer Center, Daphne, Alabama, United States
🇺🇸Western Regional Medical Center at Cancer Treatment Centers of America, Goodyear, Arizona, United States
🇺🇸Hoag Memorial Hospital, Newport Beach, California, United States
A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer
- First Posted Date
- 2020-10-12
- Last Posted Date
- 2023-03-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 83
- Registration Number
- NCT04584112
- Locations
- 🇺🇸
Tennessee Onc., PLLC - SCRI, Nashville, Tennessee, United States
🇦🇺Mater Hospital; Cancer Services, South Brisbane, Queensland, Australia
🇧🇷Hospital Sírio-Libanês, Sao Paulo, SP, Brazil
An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE)
- Conditions
- Interventions
- First Posted Date
- 2020-09-24
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 36
- Registration Number
- NCT04563338
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-09-23
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 3
- Registration Number
- NCT04560972
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
CRAFT: the NCT-PMO-1602 Phase II Trial
- Conditions
- Interventions
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- German Cancer Research Center
- Target Recruit Count
- 175
- Registration Number
- NCT04551521
- Locations
- 🇩🇪
Charité - Universitätsmedizin Berlin, Berlin, Germany
🇩🇪Nationales Centrum für Tumorerkrankungen (NCT), Heidelberg, Germany
🇩🇪Universitätsklinikum Freiburg, Freiburg, Germany
Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Oncology Institute of Southern Switzerland
- Target Recruit Count
- 12
- Registration Number
- NCT04549428
- Locations
- 🇨🇭
Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
🇨🇭Cantonal Hospital of Graubünden (KSGR), Chur, Switzerland
🇨🇭Geneva University Hospitals (HUG), Geneva, Switzerland
A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy
- Conditions
- Interventions
- First Posted Date
- 2020-09-10
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 760
- Registration Number
- NCT04543617
- Locations
- 🇺🇸
MD Anderson Cancer Center; Oncology, Houston, Texas, United States
🇿🇦Limpopo Cancer Research Institute, Polokwane, South Africa
🇺🇸Compassionate Cancer Care Medical Group, Inc, Corona, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.